Global Typhoid Fever Market - 2023-2030

Global Typhoid Fever Market - 2023-2030

The Global Typhoid Fever Market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.

Salmonella Typhi is the bacterium that causes typhoid fever. It is spread by tainted food and water and is a major public health risk in many parts of the world, especially in those with poor access to sanitary facilities and clean water. Typhoid fever treatments, vaccinations, and diagnostics make up the majority of the market.

Typhoid fever and other infectious diseases are receiving more attention from international organizations and governments. The market for related products is driven by initiatives to enhance sanitation, hygiene, and immunization coverage.

Increased demand for preventive measures is a result of public awareness efforts about the risks of typhoid fever as well as the availability of vaccinations and therapies. The market has benefited from the release of updated and new typhoid vaccinations. The demand for vaccinations rises as more nations implement vaccination programs.

Dynamics

Increasing Vaccination Program

In July 2023, in order to immunize every person between the ages of 9 months and 65, the Ministry of Health and Medical Services (MHMS) of Fiji initiated a mass vaccination program against typhoid in the Northern Division. The Typhoid in Fiji - Vaccination Toward Elimination (Ty-FIVE) project, which is being directed by the International Vaccine Institute (IVI) in collaboration with the Fijian MHMS and scientists from the Peter Doherty Institute and Murdoch Children's Research Institute, includes the public health campaign as one of its components.

Over the next 8 weeks, medical professionals in the Northern Division will give the Typbar typhoid conjugate vaccine to almost 132,000 individuals in a single dosage. Ty-FIVE will use the data gathered to evaluate the effectiveness of prophylactic immunization in an endemic context after the campaign.

The Increasing Prevalence of Typhoid Fever

The bacteria Salmonella Typhi is the source of the potentially fatal disease typhoid fever. In the US, there are thought to be 5,700 instances yearly. Up to 75% of cases are contracted when traveling abroad. In the underdeveloped world, where it affects roughly 21.5 million people yearly, typhoid fever is still widespread. Typhoid fever patients typically have a persistent temperature of 103° to 104° F (39° to 40° C).

Additionally, they can feel weak or experience headaches, nausea, or stomachaches. Patients may get a rash of flat, rose-colored patches in some circumstances. Typhoid fever can only be diagnosed with certainty through testing of stool or blood samples for Salmonella Typhi. Travelers should be advised that while both typhoid vaccines offer 50%–80% protection to recipients, typhoid illness is still a possibility.

Government Initiatives

As of September 2022, in Quetta's 39 urban union councils, 856,000 children between the ages of nine and fifteen would receive the typhoid vaccine during the first phase. Participants in the consultation session were informed that there is a strain of typhoid in Pakistan that cannot be treated medically but can be prevented by vaccination. Balochistan has begun an anti-typhoid campaign.

PHC Global is collaborating with the province government on this vaccination effort in four Balochistan districts, including Lasbela, Kech, Jafarabad, and Quetta. The vaccination had no negative side effects. DHO Quetta emphasized the necessity for raising awareness and added that as the typhoid vaccine program is new, it is necessary to promote awareness campaigns for the general public, for which all stakeholders, including civil society and the media, must play their respective roles.

The Increasing Research Activities

Typhoid conjugate vaccine (TCV) hesitancy and access, as well as practices related to water, sanitation, and hygiene, are among the risk factors that experts are evaluating in order to improve ongoing prevention and response efforts for drug-resistant typhoid in Pakistan. To equip the Pakistan Field Epidemiology Training Program with the necessary skills in this subject area, work will entail creating and implementing training materials for typhoid monitoring and outbreak response.

TCV vaccination strategies can help prevent the further spread of antimicrobial-resistant strains and reduce the risk of the development of a strain resistant to all currently available oral antibiotics, which could result in high typhoid-associated mortality in low- and middle-income countries. Extensively drug-resistant (XDR) typhoid outbreaks in Pakistan have few treatment options.

Vaccine Hesitancy

Despite the availability of vaccination facilities, vaccine hesitancy refers to the hesitation or refusal to obtain vaccinations. It can be influenced by a number of things, such as false information, a lack of faith in healthcare systems, cultural norms, and worries about the safety of vaccines. Misinformation about vaccines can cause reluctance and unwillingness to vaccinate, such as erroneous claims about side effects or conspiracy theories.

Vaccine hesitation may be exacerbated by a lack of faith in medical professionals, healthcare facilities, or vaccine producers. People do not prioritize vaccination in areas where the risk of typhoid fever is low or the illness is not thought to be severe, which results in delayed or skipped immunization. Some cultures may have cultural or religious beliefs that affect how they view vaccinations and cause reluctance.

Side Effects of Typhoid Vaccine

The oral Ty21a vaccine and the injectable Vi polysaccharide vaccine are the two most widely used typhoid vaccines. Although both vaccines are typically safe, they can have negative effects like any other medical procedure. The side effects can differ from person to person and the majority are minor and transient. Some patients encounter minor discomfort, redness, or swelling at the injection site upon receiving the injectable Vi polysaccharide vaccination.

Mild gastrointestinal symptoms like nausea, diarrhea, or stomach aches can occur in some persons. Although uncommon, adverse reactions can happen following immunization. Hives, breathing problems, neck swelling, or trouble breathing are all indications of an allergic reaction. Seek emergency medical treatment if you encounter any of these symptoms.

Segment Analysis

The global typhoid fever market is segmented based on type, route of administration, end-users and region.

Live Attenuated Vaccine

A live attenuated vaccination for oral administration exclusively, Vivotif (Typhoid vaccination Live Oral Ty21a). Salmonella typhi Ty21a, an attenuated strain, is present in the vaccine. Crucell Switzerland LTD is the company that makes Vivotif. The vaccine strain is cultivated in fermentors under carefully regulated circumstances using a medium that includes an acid digest of casein, dextrose, and galactose, as well as a digest of yeast extract. By centrifuging, the bacteria are separated, combined with a stabilizer made of sucrose, ascorbic acid, and amino acids, and then lyophilized.

In order to make the lyophilized bacteria resistant to stomach acid disintegration, they are combined with lactose and magnesium stearate and put inside gelatin capsules. The capsules are then coated with an organic solution. Vivotif (Typhoid Vaccine Live Oral Ty21a) is recommended for use in immunizing adults and children older than 6 years old against Salmonella typhi-related illness.

Geographical Penetration

The Increasing Number of Patients with Typhoid Fever in Asian Countries

Asia Pacific has been a dominant force in the global typhoid fever market. India has a high incidence of typhoid cases and the disease is endemic there. Affected areas are those with insufficient sanitation and hygiene standards. Varying states and areas have varying incidence rates. In some parts of Vietnam, typhoid fever is common, particularly in rural areas with little access to sanitary services and clean water.

Enteric fever (EF), also known as typhoid and paratyphoid fever, typically manifests as febrile symptoms accompanied by chills. A few individuals also appear with rose spots, which are typically challenging to recognize from other acute febrile infections. The majority of patients also come with gastrointestinal symptoms like abdominal pain, constipation, and diarrhea.

As per the article published in BMC Public Health in 2023, typhoid and paratyphoid are common throughout Asia, which includes China. Typhoid and paratyphoid fever are widespread in Southeast Asia, with India bearing a disproportionately heavy burden and accounting for roughly half of all deaths worldwide. China, which is a part of Asia, should monitor the situation of the disease that is coming from Southeast Asia and implement entry-exit quarantine measures.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global typhoid fever market. The COVID-19 pandemic has made it clear how crucial it is to prevent and manage infectious diseases. More funding is given by governments and healthcare institutions to combat COVID-19 as well as other infectious diseases like typhoid fever.

Due to lockdowns and health system priorities, certain regular vaccination campaigns, such as those for typhoid fever interrupted during the pandemic. Typhoid outbreaks could possibly become more likely in some areas as a result of this disruption, which could result in decreased vaccination coverage rates.

Russia-Ukraine War Impact Analysis

Conflicts can disrupt healthcare systems, making it difficult to provide basic medical services including typhoid fever diagnosis, treatment, and prevention. People are frequently displaced during conflicts as they flee their homes in search of safety. Displacement can result in congested living quarters, restricted access to sanitary services and clean water, as well as a higher risk of infectious diseases like typhoid.

Conflict-related infrastructure damage can affect water and sanitation systems, which raises the risk of waterborne illnesses like typhoid fever. Conflicts can stop routine vaccination campaigns, which lowers vaccination coverage rates and raises susceptibility to diseases that can be prevented by vaccination.

By Type
• Live Attenuated Vaccine
• Monovalent Typhoid Vaccines
• Capsular Polysaccharide Vaccines
• Conjugate Vaccine
• Others

By Route of Administration
• Oral
• Parenteral

By End-users
• Hospitals
• Specialty Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In May 2023, the Government of Malawi launched a nationwide integrated vaccine campaign to distribute measles-rubella (MR) vaccines and typhoid conjugate vaccine (TCV), with assistance from Gavi, the Vaccine Alliance, WHO, UNICEF, TyVAC, and other partners. TCV will then be incorporated into the country's routine immunization program.

Competitive Landscape
The major global players in the market include Emergent, Bharat Biotech, Bio Med, GlaxoSmithKline plc., Sanofi, and Merck & Co., Inc. and others.

Why Purchase the Report?
• To visualize the global typhoid fever market segmentation based on type, route of administration, end-users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of typhoid fever market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global typhoid fever market report would provide approximately 57 tables, 64 figures and 200 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies